Literature DB >> 19523690

The short-term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia.

Dawn I Velligan1, Pamela Diamond, Janet Mueller, Xueying Li, Natalie Maples, Mei Wang, Alexander L Miller.   

Abstract

We examined the short-term efficacy of two treatments using environmental supports (e.g. signs, alarms, pill containers, and checklists) to improve target behaviors in individuals with schizophrenia. 120 participants were randomized into one of the following three treatment groups: 1) Cognitive Adaptation Training (CAT; a manual-driven set of environmental supports customized to individual cognitive impairments and behaviors, and established and maintained in participants' homes on weekly visits; 2) Generic Environmental Supports (GES; a generic set of supports given to patients at a routine clinic visit and replaced on a monthly basis); and 3) treatment as usual (TAU; standard follow-up provided by a community mental health center). Global level of functional outcome and target behaviors, including orientation, grooming and hygiene, and medication adherence, were assessed at baseline and 3 months. Results of an analysis of covariance indicated that patients in both CAT and GES had better scores on global functional outcome at 3 months than those in TAU. Results of Chi Square analyses indicated that patients in CAT were more likely to improve on target behaviors, including orientation, hygiene, and medication adherence, than those in GES. Irrespective of treatment group, individuals who were high utilizers of environmental supports were more likely to improve on target behaviors than individuals who were low utilizers of supports.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523690      PMCID: PMC2752323          DOI: 10.1016/j.psychres.2008.03.016

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  15 in total

1.  Two case studies of cognitive adaptation training for outpatients with schizophrenia.

Authors:  D I Velligan; C C Bow-Thomas
Journal:  Psychiatr Serv       Date:  2000-01       Impact factor: 3.084

2.  Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.

Authors:  Dawn I Velligan; Francis Lam; Larry Ereshefsky; Alexander L Miller
Journal:  Psychiatr Serv       Date:  2003-05       Impact factor: 3.084

Review 3.  Executive function in schizophrenia.

Authors:  D I Velligan; C C Bow-Thomas
Journal:  Semin Clin Neuropsychiatry       Date:  1999-01

4.  The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia.

Authors:  L D Alphs; A Summerfelt; H Lann; R J Muller
Journal:  Psychopharmacol Bull       Date:  1989

5.  A community ability scale for chronically mentally ill consumers: Part I. Reliability and validity.

Authors:  S Barker; N Barron; B H McFarland; D A Bigelow
Journal:  Community Ment Health J       Date:  1994-08

6.  Neuropsychological function in schizophrenia. Selective impairment in memory and learning.

Authors:  A J Saykin; R C Gur; R E Gur; P D Mozley; L H Mozley; S M Resnick; D B Kester; P Stafiniak
Journal:  Arch Gen Psychiatry       Date:  1991-07

7.  Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?

Authors:  D I Velligan; C C Bow-Thomas; R K Mahurin; A L Miller; L C Halgunseth
Journal:  J Nerv Ment Dis       Date:  2000-08       Impact factor: 2.254

Review 8.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

Review 9.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

10.  Development and Pilot Testing of a Novel Compensatory Cognitive Training Intervention for People with Psychosis.

Authors:  Elizabeth W Twamley; Gauri N Savla; Cynthia H Zurhellen; Robert K Heaton; Dilip V Jeste
Journal:  Am J Psychiatr Rehabil       Date:  2008-04
View more
  5 in total

1.  A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.

Authors:  Dawn I Velligan; David Roberts; Jim Mintz; Natalie Maples; Xueying Li; Elisa Medellin; Matt Brown
Journal:  Schizophr Res       Date:  2015-05-01       Impact factor: 4.939

2.  The feasibility of cognitive adaptation training for outpatients with schizophrenia in integrated treatment.

Authors:  Jens Peter Hansen; Birte Østergaard; Merete Nordentoft; Lise Hounsgaard
Journal:  Community Ment Health J       Date:  2012-10-12

Review 3.  Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia.

Authors:  Melissa Fisher; Rachel Loewy; Kate Hardy; Danielle Schlosser; Sophia Vinogradov
Journal:  Annu Rev Clin Psychol       Date:  2013-01-07       Impact factor: 18.561

4.  In-office, in-home, and telehealth cognitive processing therapy for posttraumatic stress disorder in veterans: a randomized clinical trial.

Authors:  Alan L Peterson; Jim Mintz; John C Moring; Casey L Straud; Stacey Young-McCaughan; Cindy A McGeary; Donald D McGeary; Brett T Litz; Dawn I Velligan; Alexandra Macdonald; Emma Mata-Galan; Stephen L Holliday; Kirsten H Dillon; John D Roache; Lindsay M Bira; Paul S Nabity; Elisa M Medellin; Willie J Hale; Patricia A Resick
Journal:  BMC Psychiatry       Date:  2022-01-17       Impact factor: 3.630

Review 5.  Efficacy of community treatments for schizophrenia and other psychotic disorders: a literature review.

Authors:  Julio Armijo; Emmanuel Méndez; Ricardo Morales; Sara Schilling; Ariel Castro; Rubén Alvarado; Graciela Rojas
Journal:  Front Psychiatry       Date:  2013-10-09       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.